Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10162381 | 0.94 | HRH3 (0.43) | HRH3L3MBTL3L3MBTL1MBTD1CHRM2 | |
| SCHEMBL22456382 | 0.94 | HRH3 (0.49) | HRH3L3MBTL3L3MBTL1MBTD1CHRM2 | |
| SCHEMBL10092689 | 0.92 | HRH3 (0.50) | HRH3CHRM2CHRM1TP53TSHR | |
| SCHEMBL3439846 | 0.92 | L3MBTL3 (0.48) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL25050072 | 0.90 | L3MBTL3 (0.44) | HRH3L3MBTL3L3MBTL1MBTD1HTR6 | |
| SCHEMBL24742908 | 0.90 | HRH3 (0.47) | HRH3CHRM2CHRM1TP53TSHR | |
| SCHEMBL8186259 | 0.90 | HRH3 (0.53) | HRH3CHRM2CHRM1TP53TSHR | |
| SCHEMBL12858869 | 0.90 | HRH3 (0.53) | HRH3CHRM2CHRM1TP53TSHR | |
| SCHEMBL8255448 | 0.90 | L3MBTL3 (0.47) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL278657 | 0.90 | L3MBTL3 (0.47) | HRH3L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8404719-B2 | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | HRH3 378/4885L3MBTL3 2063/4885L3MBTL1 1498/4885 |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | HRH3 378/4885L3MBTL3 2063/4885L3MBTL1 1498/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | HRH3 378/4885L3MBTL3 2063/4885L3MBTL1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.